Killer Immunoglobulin-like Receptor (KIR) and HLA Genotypes Affect the Outcome of Allogeneic Kidney Transplantation

PLoS ONE

Volumn 7, Issue 9, 2012, Pages

  Nowak, Izabela ^a   Magott Procelewska, Maria ^b   Kowal, Agnieszka ^a   Miazga, Maciej ^a   Wagner, Marta ^a   Niepiekło Miniewska, Wanda ^a   Kamińska, Małgorzata ^a   Wiśniewski, Andrzej ^a   Majorczyk, Edyta ^a   Klinger, Marian ^b   Łuszczek, Wioleta ^a   Pawlik, Andrzej ^c   Płoski, Rafał ^d   Barcz, Ewa ^d   Senitzer, David ^e   Kuśnierczyk, Piotr ^a  

^a INSTITUTE OF IMMUNOLOGY AND EXPERIMENTAL THERAPY   (Poland)

^b WROCLAW MEDICAL UNIVERSITY   (Poland)

^c POMERANIAN MEDICAL UNIVERSITY   (Poland)

^d MEDICAL UNIVERSITY OF WARSAW   (Poland)

^e CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CYCLOSPORIN A; HLA ANTIGEN; HLA B ANTIGEN; HLA DR ANTIGEN; KILLER CELL IMMUNOGLOBULIN LIKE RECEPTOR; KILLER CELL IMMUNOGLOBULIN LIKE RECEPTOR 2DL4; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; STEROID; TACROLIMUS;

ACUTE GRAFT REJECTION; ADOLESCENT; ADULT; AGED; ALLOTRANSPLANTATION; ARTICLE; CONTROLLED STUDY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; GENE; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOTYPE; GLOMERULONEPHRITIS; HLA MATCHING; HLA TYPING; HUMAN; HUMAN TISSUE; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; KILLER IMMUNOGLOBULIN LIKE RECEPTOR GENE; KIR2DS4 GENE; KIR2DS5 GENE; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION;

ADOLESCENT; ADULT; AGED; FEMALE; GENOTYPE; HLA ANTIGENS; HUMANS; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; MODELS, THEORETICAL; RECEPTORS, KIR; TRANSPLANTATION, HOMOLOGOUS; YOUNG ADULT;

EID: 84866398555     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0044718     Document Type: Article

References (43)

1. Womer KL, Kaplan B, (2009) Recent developments in kidney transplantation - a critical assessment. Am J Transplant 9: 1265-1271.
2. Nankivell BJ, Alexander SI, (2010) Rejection of the kidney allograft. N Engl J Med 363: 1451-1462.
3. Andersen CB, Ladefoged SD, Larsen S, (1994) Acute kidney graft rejection. A morphological and immunohistochemical study on 'zero-hour' and follow-up biopsies with special emphasis on cellular infiltrates and adhesion molecules. APMIS 102: 23-37.
4. Hancock WW, Gee D, De Moerloose P, Rickles FR, Ewan VA, et al. (1985) Immunohistological analysis of serial biopsies taken during human renal allograft rejection. Changing profile of infiltrating cells and activation of the coagulation system. Transplantation 39: 430-438.
5. Totterman TH, Hanas E, Bergstrom R, Larsson E, Tufveson G, (1989) Immunologic diagnosis of kidney rejection using FACS analysis of graft-infiltrating functional and activated T and NK cell subsets. Transplantation 47: 817-823.
6. Cooksey G, Robins RA, Blamey RW, (1984) Natural killer cells in renal allograft rejection. Br J Surg 71: 874-877.
7. Vampa ML, Norman PJ, Burnapp L, Vaughan RW, Sacks SH, et al. (2003) Natural killer-cell activity after human renal transplantation in relation to killer immunoglobulin-like receptors and human leukocyte antigen mismatch. Transplantation 76: 1220-1228.
8. Parham P, (2005) MHC class I molecules and KIRs in human history, health and survival. Nature Rev Immunol 5: 201-214.
9. Moretta L, Locatelli F, Pende D, Marcenaro E, Mingari MC, et al. (2011) Killer Ig-like receptor-mediated control of natural killer cell alloreactivity in haploidentical hematopoietic stem cell transplantation. Blood 117: 764-771.
10. Velardi A, Ruggeri L, Mancusi A, Aversa F, Christiansen FT, (2009) Natural killer cell allorecognition of missing self in allogeneic hematopoietic transplantation: a tool for immunotherapy of leukemia. Curr Opin Immunol 21: 525-530.
11. Pegram HJ, Ritchie DS, Smyth MJ, Wiernik A, Prince HM, et al. (2011) Alloreactive natural killer cells in hematopoietic stem cell transplantation. Leuk Res 35: 14-21.
12. Weng N-P, Akbar AN, Goronzy J, (2009) CD28- T cells: their role in the age-associated decline of immune function. Trends Immunol 30: 306-312.
13. Snyder MR, Nakajima T, Leibson PJ, Weyand CM, Goronzy JJ, (2004) Stimulatory killer Ig-like receptors modulate T cell activation through DAP12-dependent and DAP12-independent mechanisms. J Immunol 173: 3725-3731.
14. Thewissen M, Somers V, Hellings N, Fraussen J, Damoiseaux J, et al. (2007) CD4+CD28null T cells in autoimmune disease: Pathogenic features and decreased susceptibility to immunoregulation. J Immunol 179: 6514-6523.
15. Middleton D, Meenagh A, Moscoso J, Arnaiz-Villena A, (2008) Killer immunoglobulin receptor gene and allele frequencies in Caucasoid, Oriental and Black populations from different continents. Tissue Antigens 71: 105-113.
16. Middleton D, Gonzelez F, (2009) The extensive polymorphism of KIR genes. Immunology 129: 8-19.
17. Shilling HG, Young N, Guethlein LA, Cheng NW, Gardiner CM, et al. (2002) Genetic control of human NK repertoire. J Immunol 169: 239-247.
18. Nowak I, Majorczyk E, Wiśniewski A, Pawlik A, Magott-Procelewska M, et al. (2010) Does the KIR2DS5 gene protect from some human diseases? PLoS ONE 5: e12381.
19. Racusen LC, Solez K, Colvin RB, Bonsib SM, Castro MC, et al. (1999) The Banff 97 working classification of renal allograft pathology. Kidney International 55: 713-723.
20. Majorczyk E, Pawlik A, Łuszczek W, Nowak I, Wiśniewski A, et al. (2007) Associations of killer cell immunoglobulin-like receptor genes with complications of rheumatoid arthritis. Genes Immunity 8: 678-683.
21. Łuszczek W, Mańczak M, Cisło M, Nockowski P, Wiśniewski A, et al. (2004) Gene for the activating natural killer cell receptor, KIR2DS1, is associated with susceptibility to psoriasis vulgaris. Hum Immunol 65: 758-766.
22. Vilches C, Castaño J, Gómez-Lozano N, Estefanía E, (2007) Facilitation of KIR genotyping by a PCR-SSP method that amplifies short DNA fragments. Tissue Antigens 70: 415-422.
23. Sun JY, Gaidulis L, Miller MM, Goto RM, Rodriguez R, et al. (2004) Development of a multiplex PCR-SSP method for killer cell immunoglobulin-like receptor genotyping. Tissue Antigens 64: 462-468.
24. Excoffier L, Slatkin M, (1995) Maximum-likelihood estimation of molecular haplotype frequencies in a diploid population. Mol Biol Evol 12: 921-927.
25. Abdallah JM, Goffinet B, Cierco-Ayrolles C, Pérez-Enciso M, (2003) Linkage disequilibrium fine mapping of quantitative trait loci: a simulation study. Genet Sel Evol 35: 513-532.
26. Bhasi K, Zhang L, Brazeau D, Zhang A, Ramanathan M, (2006) Information-theoretic identification of predictive SNPs and supervised visualization of genome-wide association studies. Nucleic Acids Res 34: e101.
27. Liu Z, Lin S, (2005) Multilocus LD measure and tagging SNP selection with generalized mutual information. Genet Epidemiol 29: 353-364.
28. Single RM, Martin MP, Meyer D, Gao X, Carrington M, (2008) Methods for assessing gene content diversity of KIR with examples from a global set of populations. Immunogenetics 60: 711-725.
29. Yen JH, Moore BE, Nakajima T, Scholl D, Schaid DJ, et al. (2001) Major histocompatibility complex class I-recognizing receptors are disease risk genes in rheumatoid arthritis. J Exp Med 193: 1159-1167.
30. Yadav AK, Jha V, (2011) CD4+CD28null cells are expanded and exhibit a cytolytic profile in end-stage renal disease patients on peritoneal dialysis. Nephrol Dial Transplant 26: 1689-1694.
31. Betjes MGH, Huisman M, Weimar W, Litjens NHR, (2008) Expansion of cytolytic CD4+CD28- T cells in end-stage renal disease. Kidney International 74: 760-767.
32. Middleton D, Gonzalez A, Gilmore PM, (2007) Studies on the expression of the deleted KIR2DS4*003 gene product and distribution of KIR2DS4 deleted and nondeleted versions in different populations. Hum Immunol 68: 128-134.
33. van der Meer A, Schaap NPM, Schattenberg AVMB, van Cranenbroek B, Tijssen HJ, Joosten I, (2998) KIR2DS5 is associated with leukemia free survival after HLA identical stem cell transplantation in chronic myeloid leukemia patients. Molec Immunol 45: 3631-3638.
34. Graef T, Moesta AK, Norman PJ, Abi-Rached L, Vago L, et al. (2009) KIR2DS4 is a product of gene conversion with KIR3DL2 that introduced specificity for HLA-A*11 while diminishing avidity for HLA-C. J Exp Med 206: 2557-2572.
35. Hanvesakul R, Kubal C, Moore J, Neil D, Cook M, Ball S, et al. (2011) KIR and HLA-C interactions promote differential dendritic cell maturation and is a major determinant of graft failure following kidney transplantation. PLoS ONE 6: e23631.
36. Schmidt AH, Solloch UV, Pingel J, Baier D, Böhme I, et al. (2011) High resolution human leukocyte antigen allele and haplotype frequencies of the Polish population based on 20,653 stem cell donors. Hum Immunol 72: 558-565.
37. Tran TH, Mytilineos J, Scherer S, Laux G, Middleton D, et al. (2005) Analysis of KIR ligand incompatibility in human renal transplantation. Transplantation 80: 1121-1123.
38. Kreijveld E, van der Meer A, Tijssen HJ, Hilbrands LB, Joosten I, (2007) KIR gene and KIR ligand analysis to predict graft rejection after renal transplantation. Transplantation 84: 1045-1051.
39. Cirocco RE, Mathew JM, Burke GW 3rd, Esquenazi V, Miller J, (2007) Killer cell immunoglobulin-like receptor polymorphisms in HLA-identical kidney transplant recipients: lack of 2DL2 and 2DS2 may be associated with poor graft function. Tissue Antigens 69 (Suppl 1):: S123-S124.
40. Kunert K, Seiler M, Mashreghi MF, Klippert K, Schönemann C, et al. (2007) KIR/HLA ligand incompatibility in kidney transplantation. Transplantation 84: 1527-1533.
41. van Bergen J, Thompson A, Haasnoot GW, Roodnat JI, de Fijter JW, et al. (2011) KIR-ligand mismatches are associated with reduced long-term graft survival in HLA-compatible kidney transplantation. Am J Transplant 11: 1959-1964.
42. Rajalingam R, Gebel HM, (2011) KIR-HLA mismatching in human renal allograft transplantation: Emergence of a new concept. Am J Transplant 11: 1771-1772.
43. López-Álvarez MR, Campillo JA, Legaz I, Blanco-García RM, Salgado-Cecilia G, et al. (2011) Divergences in KIR2D+ natural killer and KIR2D+ CD8+ T-cell reconstitution following liver transplantation. Hum Immunol 72: 229-237.